A significantly higher proportion of patients in the cetuximab plus pemetrexed group ( @ -LSB- @ % -RSB- of @ patients ) experienced at least one serious adverse event than those patients in the pemetrexed group ( @ -LSB- @ % -RSB- of @ patients ; p = @ ) .